Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Eupraxia Pharmaceuticals has a consensus “Moderate Buy” rating from nine analysts, with five buys, two strong buys, one hold and one sell. The average 12-month price target is $18.00, roughly double the reported $8.64 share price.
• The company’s latest quarterly results exceeded expectations, reporting a loss of $0.23 per share versus the $0.25 consensus estimate. Analysts expect a full-year loss of approximately $0.85 per share.
• Institutional ownership has increased, with investors including Royal Bank of Canada, AXQ Capital and Bank of America adding to their positions, while Eupraxia continues developing targeted, extended-release therapies led by its EP-104I osteoarthritis candidate.

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the nine brokerages that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $18.00.

A number of equities analysts have recently issued reports on EPRX shares. Oppenheimer assumed coverage on Eupraxia Pharmaceuticals in a research note on Thursday, June 25th. They issued an "outperform" rating and a $17.00 price target on the stock. Cantor Fitzgerald reissued an "overweight" rating on shares of Eupraxia Pharmaceuticals in a research note on Wednesday, July 15th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Eupraxia Pharmaceuticals in a research report on Friday, July 17th. Finally, Wall Street Zen upgraded shares of Eupraxia Pharmaceuticals from a "strong sell" rating to a "sell" rating in a report on Saturday, September 12th.

Eupraxia Pharmaceuticals Price Performance

NASDAQ EPRX opened at $8.64 on Tuesday. Eupraxia Pharmaceuticals has a one year low of $5.16 and a one year high of $9.32. The stock has a 50-day moving average of $7.03 and a 200 day moving average of $6.99. The company has a market capitalization of $561.77 million, a price-to-earnings ratio of -8.47 and a beta of 1.07. The company has a debt-to-equity ratio of 0.02, a quick ratio of 16.00 and a current ratio of 16.00.

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.02. On average, sell-side analysts forecast that Eupraxia Pharmaceuticals will post -0.85 EPS for the current year.

Institutional Trading of Eupraxia Pharmaceuticals

A number of large investors have recently made changes to their positions in the business. Persistent Asset Partners Ltd bought a new position in shares of Eupraxia Pharmaceuticals during the 2nd quarter valued at approximately $25,000. AXQ Capital LP increased its stake in Eupraxia Pharmaceuticals by 34.2% in the 2nd quarter. AXQ Capital LP now owns 21,150 shares of the company's stock worth $140,000 after buying an additional 5,390 shares during the period. BlackRock Inc. purchased a new position in shares of Eupraxia Pharmaceuticals during the second quarter worth approximately $40,000. Bank of America Corp DE raised its position in Eupraxia Pharmaceuticals by 5.9% during the 1st quarter. Bank of America Corp DE now owns 268,221 shares of the company's stock valued at $1,942,000 after purchasing an additional 14,900 shares in the last quarter. Finally, Royal Bank of Canada raised its holdings in shares of Eupraxia Pharmaceuticals by 33.2% in the first quarter. Royal Bank of Canada now owns 261,376 shares of the company's stock valued at $1,893,000 after acquiring an additional 65,099 shares in the last quarter.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc NASDAQ: EPRX is a clinical-stage biotechnology company based in Canada. The company develops locally administered therapies intended to treat inflammatory, fibrotic and other diseases while limiting patients' exposure to medication throughout the body.

Eupraxia's development programs are built around its proprietary Diffusion Driven Drug Delivery (3D) platform. The technology is designed to provide controlled, sustained release of pharmaceutical compounds at targeted sites, potentially extending treatment effects and reducing systemic side effects.

The company's lead product candidate, EP-104I, is an extended-release formulation of fluticasone propionate being developed for intra-articular administration in patients with osteoarthritis of the knee.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.